About Synthetic Biologics (NYSEAMERICAN:SYN)
Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates in Phase III development include SYN-010, which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase) that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD), and the emergence of antimicrobial resistance (AMR). The company is also developing SYN-007 and SYN-006 for the prevention of CDI and AAD; SYN-005, a monoclonal antibody therapy for the prevention and treatment of pertussis; SYN-200 for the treatment of phenylketonuria; and SYN-020, an oral dosage form of intestinal alkaline phosphatase. It has collaboration agreements with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets53.56%
Miscellaneous
EmployeesN/A
Outstanding Shares128,570,000
Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions
What is Synthetic Biologics' stock symbol?
Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."
How were Synthetic Biologics' earnings last quarter?
Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) released its quarterly earnings results on Thursday, February, 22nd. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.07. View Synthetic Biologics' Earnings History.
What price target have analysts set for SYN?
1 analysts have issued twelve-month price targets for Synthetic Biologics' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Synthetic Biologics' share price to reach $5.00 in the next year. View Analyst Ratings for Synthetic Biologics.
Are investors shorting Synthetic Biologics?
Synthetic Biologics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 4,654,391 shares, an increase of 4.3% from the March 15th total of 4,461,483 shares. Based on an average trading volume of 561,547 shares, the days-to-cover ratio is presently 8.3 days. Approximately 4.0% of the shares of the stock are sold short.
Who are some of Synthetic Biologics' key competitors?
Some companies that are related to Synthetic Biologics include Orchids Paper Products (TIS), inTest (INTT), Matinas BioPharma (MTNB), Ur-energy (URG), Contango Oil & Gas (MCF), Unique Fabricating (UFAB), Transatlantic Petroleum (TAT), Bovie Medical (BVX), CPI Aerostructures (CVU), Vista Gold (VGZ), Globalscape (GSB), Acme United (ACU), UQM Technologies (UQM), McClatchy (MNI), eMagin (EMAN), OncoCyte (OCX), Avino Silver & Gold Mines (ASM) and Plymouth Industrial Reit (PLYM).
Who are Synthetic Biologics' key executives?
Synthetic Biologics' management team includes the folowing people:
- Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
- Dr. Joseph A. Sliman M.D., MPH, Chief Medical Officer (Age 45)
- Vincent I. Perrone, Director of Corp. Communication
- Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
- Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing
Has Synthetic Biologics been receiving favorable news coverage?
Media headlines about SYN stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synthetic Biologics earned a media sentiment score of 0.13 on Accern's scale. They also gave media stories about the company an impact score of 46.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Synthetic Biologics?
Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synthetic Biologics' stock price today?
One share of SYN stock can currently be purchased for approximately $0.34.
How big of a company is Synthetic Biologics?
Synthetic Biologics has a market capitalization of $49.23 million.
How can I contact Synthetic Biologics?
Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.
MarketBeat Community Rating for Synthetic Biologics (SYN)
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Synthetic Biologics (NYSEAMERICAN:SYN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Synthetic Biologics in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 1,370.59%. The high price target for SYN is $5.00 and the low price target for SYN is $5.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $5.00 | $5.00 | $5.50 |
| Price Target Upside: | 1,370.59% upside | 863.39% upside | 863.39% upside | 959.73% upside |
Synthetic Biologics (NYSEAMERICAN:SYN) Consensus Price Target History
Synthetic Biologics (NYSEAMERICAN:SYN) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Synthetic Biologics (NYSEAMERICAN:SYN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Synthetic Biologics (NYSEAMERICAN SYN) Insider Trading and Institutional Ownership History
Synthetic Biologics (NYSEAMERICAN SYN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/17/2015 | Brendan Cannon | Director | Buy | 5,000 | $0.3850 | $1,925.00 | | |
| 11/30/2015 | Christoper Martin | Director | Buy | 80,000 | $0.40 | $32,000.00 | | |
| 11/27/2015 | Bartley Vaden Heath | Director | Buy | 35,000 | $0.28 | $9,800.00 | | |
| 9/2/2015 | Randal J Kirk | Major Shareholder | Buy | 937,500 | $3.20 | $3,000,000.00 | |  |
| 5/22/2014 | Charles Evan Ballantyne | CFO | Buy | 10,000 | $1.35 | $13,500.00 | | |
| 4/29/2014 | Steve H Kanzer | Director | Sell | 263,112 | $2.90 | $763,024.80 | | |
| 12/17/2013 | Randal J Kirk | Major Shareholder | Buy | 2,500,000 | $1.00 | $2,500,000.00 | | |
| 1/7/2013 | Jeffrey Scott Riley | CEO | Buy | 2,900 | $0.17 | $493.00 | | |
| 1/3/2013 | Jeffrey Scott Riley | CEO | Buy | 2,000 | $1.71 | $3,420.00 | | |
| 10/29/2012 | Randal J Kirk | Major Shareholder | Buy | 3,125,000 | $1.60 | $5,000,000.00 | | |
(Data available from 1/1/2013 forward)
Synthetic Biologics (NYSEAMERICAN SYN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Global Synthetic Biology Market: Widening Application Base to Boost Market’s Growth, Says TMR
globenewswire.com - April 19 at 9:21 AM |
 | Synthetic Biologics (SYN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 12 at 11:29 AM |
| Synthetic Biologics, Inc. (SYN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 10 at 6:58 PM |
 | SGI-DNA Launches Automated Gene Libraries for Accelerated Drug Discovery and Development Research
www.bizjournals.com - March 29 at 9:19 AM |
| Synthetic Biologics (SYN) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 28 at 7:04 PM |
| Short Interest in Synthetic Biologics Inc (SYN) Drops By 9.1%
www.americanbankingnews.com - March 27 at 1:54 AM |
 | Pre-Market Technical Scan on Biotech Equities -- Sorrento Therapeutics, Spark Therapeutics, Synthetic Biologics, and TG Therapeutics
www.prnewswire.com - March 15 at 10:10 AM |
| Synthetic Biologics (SYN) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 14 at 10:53 AM |
| Synthetic Biologics (SYN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 13 at 3:58 PM |
| Short Interest in Synthetic Biologics Inc (SYN) Expands By 0.7%
www.americanbankingnews.com - March 9 at 6:02 PM |
| Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan - PR Newswire (press release)
www.prnewswire.com - March 7 at 4:52 PM |
 | Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
finance.yahoo.com - March 7 at 4:52 PM |
| Synthetic Biologics Inc (SYN) Short Interest Up 15.3% in February
www.americanbankingnews.com - February 27 at 5:40 PM |
| William Blair Comments on Synthetic Biologics Inc's Q1 2018 Earnings (SYN)
www.americanbankingnews.com - February 26 at 1:46 AM |
| Synthetic Biologics (SYN) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - February 24 at 4:26 PM |
| Synthetic Biologics (SYN) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - February 23 at 5:18 PM |
| Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results
finance.yahoo.com - February 22 at 9:00 AM |
| Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018
finance.yahoo.com - February 15 at 4:55 PM |
| Synthetic Biologics Inc (SYN) Sees Large Decline in Short Interest
www.americanbankingnews.com - February 9 at 6:36 PM |
| Stock Review for Biotech's Investors -- Spark Therapeutics, Synthetic Biologics, TG Therapeutics, and Zosano Pharma - PR Newswire (press release)
www.prnewswire.com - February 6 at 3:25 PM |
| Synthetic Biologics Inc (SYN) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - January 25 at 1:32 AM |
| Synthetic Biologics Inc (SYN) Short Interest Update
www.americanbankingnews.com - January 11 at 1:22 AM |
| Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference - PR Newswire (press release)
www.prnewswire.com - January 2 at 9:33 PM |
| Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference
finance.yahoo.com - January 2 at 4:33 PM |
| Synthetic Biologics Inc (SYN) Short Interest Down 13.1% in December
www.americanbankingnews.com - December 28 at 2:09 AM |
| Synthetic Biologics, Inc. (SYN) Short Interest Down 10.2% in November
www.americanbankingnews.com - December 12 at 1:50 AM |
| Synthetic Biologics Announces Management Changes - PR Newswire - PR Newswire (press release)
www.prnewswire.com - December 5 at 3:29 PM |
| Synthetic Biologics, Inc. (SYN) Short Interest Down 12.6% in November
www.americanbankingnews.com - November 27 at 9:30 PM |
| ImmunoPrecise Realigns Senior Management
finance.yahoo.com - November 20 at 10:41 AM |
Synthetic Biologics (NYSEAMERICAN:SYN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Synthetic Biologics (NYSEAMERICAN:SYN) Income Statement, Balance Sheet and Cash Flow Statement
Synthetic Biologics (NYSEAMERICAN SYN) Stock Chart for Thursday, April, 19, 2018
Loading chart…
